Stryker Corporation $SYK is Marks Group Wealth Management Inc’s 10th Largest Position

Marks Group Wealth Management Inc lowered its stake in Stryker Corporation (NYSE:SYK) by 14.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 44,057 shares of the medical technology company’s stock after selling 7,418 shares during the quarter. Stryker makes up 1.5% of Marks Group Wealth Management Inc’s investment portfolio, making the stock its 10th largest position. Marks Group Wealth Management Inc’s holdings in Stryker were worth $15,485,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Czech National Bank raised its holdings in shares of Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after acquiring an additional 3,366 shares in the last quarter. Davis R M Inc. raised its holdings in shares of Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after acquiring an additional 2,512 shares in the last quarter. Kepler Cheuvreux Suisse SA purchased a new stake in shares of Stryker in the 3rd quarter valued at about $27,952,000. Daymark Wealth Partners LLC raised its holdings in shares of Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after acquiring an additional 37,307 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC raised its holdings in shares of Stryker by 265.2% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock valued at $3,278,000 after acquiring an additional 6,774 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $465.00 price target on shares of Stryker in a report on Wednesday, March 4th. UBS Group lowered their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Wells Fargo & Company lowered their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, Evercore set a $355.00 price target on Stryker in a report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 over the last quarter. 4.60% of the stock is owned by corporate insiders.

Stryker Stock Down 1.3%

Shares of SYK opened at $301.75 on Tuesday. The firm has a market cap of $115.68 billion, a P/E ratio of 34.92, a P/E/G ratio of 1.93 and a beta of 0.78. The stock has a 50 day simple moving average of $317.81 and a two-hundred day simple moving average of $345.36. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.